PRAMEF2

Across TCGA pan-cancer cohorts, PRAMEF2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRAMEF2 data layer compared with 13 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher PRAMEF2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF2 expression acts as an unfavorable survival marker.

KICH and ESCA are the cancer types where PRAMEF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
ESCA	OS	Median	All	0.211	0.876	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRAMEF2–KICH (DFS)

Open the KICH breakdown →